Novartis, CH0012005267

Novartis stock: FDA approves Cosentyx for polymyalgia rheumatica

Published on 11/18/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock gets a new U.S. indication for Cosentyx in polymyalgia rheumatica. The approval marks the drug's 11th U.S. indication.

FDA expands Cosentyx use

  • The FDA approved Cosentyx for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering.
  • The decision gives Cosentyx its 11th approved indication in the United States.
  • In the Phase III REPLENISH trial, sustained remission at week 52 reached 40.5 percent with Cosentyx 150 mg versus 20.5 percent with placebo.
Novartis, CH0012005267, Illustration mit AI erstellt.

On November 17, Novartis said in a company press release that the U.S. Food and Drug Administration approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica, or PMR. The indication covers patients who have responded inadequately to corticosteroids or cannot tolerate a corticosteroid taper.

Cosentyx is the first and only anti-interleukin-17 biologic approved in the United States for PMR, according to Novartis. The decision expands the medicine's U.S. label to 11 indications and gives physicians an option beyond prolonged steroid treatment in a disease that can cause pain and stiffness in the shoulders, neck and hips.

Trial results support approval

The FDA decision was based on the Phase III REPLENISH trial, a randomized, double-blind study conducted across 27 countries. Participants received Cosentyx at 150 mg or 300 mg, or placebo, alongside a 24-week steroid taper.

At week 52, sustained remission was achieved by 40.5 percent of patients receiving the 150 mg dose, compared with 20.5 percent of those receiving placebo. Novartis said the trial also evaluated complete sustained remission, cumulative steroid exposure and the time to escape or rescue treatment.

The reported safety profile remained consistent with the established Cosentyx profile. Serious adverse events occurred in 15.9 percent of patients in the 150 mg group and 14.2 percent in the placebo group. Hypersensitivity reactions occurred in 14 percent and 9 percent, respectively, while urinary tract infections occurred in 13 percent and 7 percent.

Regulatory expansion continues

Novartis said the PMR indication is already approved in the European Union and that regulatory reviews are continuing in additional markets, including Japan. The company also said it had filed the REPLENISH results for review in Japan and other countries.

Novartis stock traded at 143.76 euros on Lang & Schwarz at 11:52 CET on Wednesday, November 18.

Novartis company facts

  • Company: Novartis AG
  • ISIN: CH0012005267
  • WKN: 904278
  • Quote: 143.76 euros on Lang & Schwarz, November 18, 2026, 11:52 CET

Swiss equities are tracked through the SMI.

More news and analyses on Novartis stock

Disclaimer...
en | CH0012005267 | NOVARTIS | boerse | 70530558 | bgmi